Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
Abstract Idecabtagene vicleucel (ide‐cel; bb2121) is a B‐cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This analysis evaluated exposure-response (ER) relationships o...
Saved in:
Main Authors: | , , , , , , , |
---|---|
格式: | 圖書 |
出版: |
Wiley,
2023-11-01T00:00:00Z.
|
主題: | |
在線閱讀: | Connect to this object online. |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
因特網
Connect to this object online.3rd Floor Main Library
索引號: |
A1234.567 |
---|---|
復印件 1 | 可用 |